Literature DB >> 23540786

Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how?

Chad R Ritch1, Peter E Clark, Todd M Morgan.   

Abstract

The rate of clinical understaging in non-muscle invasive bladder cancer (NMIBC) after an initial transurethral resection (TUR) is significant, particularly for high-grade disease, and this has a major impact on prognosis. A repeat TUR, 2 to 6 weeks following the initial resection, is recommended in appropriately selected cases to avoid diagnostic inaccuracy and improve treatment allocation. This article summarizes the rationale and indications for performing a repeat TUR in NMIBC and also provides information regarding patient selection and technique.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23540786     DOI: 10.1016/j.ucl.2013.01.009

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  4 in total

1.  The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.

Authors:  Paolo Gontero; Richard Sylvester; Francesca Pisano; Steven Joniau; Marco Oderda; Vincenzo Serretta; Stéphane Larré; Savino Di Stasi; Bas Van Rhijn; Alfred J Witjes; Anne J Grotenhuis; Renzo Colombo; Alberto Briganti; Marek Babjuk; Viktor Soukup; Per-Uno Malmström; Jacques Irani; Nuria Malats; Jack Baniel; Roy Mano; Tommaso Cai; Eugene K Cha; Peter Ardelt; John Vakarakis; Riccardo Bartoletti; Guido Dalbagni; Shahrokh F Shariat; Evanguelos Xylinas; Robert J Karnes; Joan Palou
Journal:  BJU Int       Date:  2015-11-06       Impact factor: 5.588

2.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

3.  Does restaging transurethral resection of bladder tumour influence outcomes in patients treated with BCG immunotherapy? 491 cases in 20 years' experience.

Authors:  Wojciech Krajewski; Romuald Zdrojowy; Katarzyna Kościelska-Kasprzak; Janusz Dembowski; Michał Wróbel; Mateusz Łuczak; Anna Kołodziej
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2018-12-19       Impact factor: 1.195

4.  Can a second resection be avoided after initial thulium laser endoscopic en bloc resection for non-muscle invasive bladder cancer? A retrospective single-center study of 251 patients.

Authors:  Wenhao Zhou; Wei Wang; Wenbo Wu; Tingmang Yan; Guofang Du; Haitao Liu
Journal:  BMC Urol       Date:  2020-03-18       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.